ALEC

Alector Inc

Add to Watchlist

Advanced Chart

2.350

-0.04(-1.674%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.440

Open

2.390

VWAP

2.35

Vol

465.08K

Mkt Cap

237.85M

Low

2.310

Amount

1.09M

EV/EBITDA(TTM)

Total Shares

96.38M

-59.90M

EV/OCF(TTM)

P/S(TTM)

2.86

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

0.00

-100%

-0.480

+17.07%

2.81M

-94.82%

-0.414

+1970%

3.49M

-77.27%

-0.382

-11.16%

Estimates Revision

The market is revising Upward the revenue expectations for Alector, Inc. (ALEC) for FY2025, with the revenue forecasts being adjusted by 41.23% over the past three months. During the same period, the stock price has changed by 70.29%.

Revenue Estimates for FY2025

Revise Upward

+41.23%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-21.65%

In Past 3 Month

Stock Price

Go Up

+70.29%

In Past 3 Month

6 Analyst Rating

75.74% Upside

Wall Street analysts forecast ALEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALEC is 4.13 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

1 Sell

Moderate Buy

75.74% Upside

Current: 2.350

Low

1.00

Averages

4.13

High

10.00

75.74% Upside

Current: 2.350

Low

1.00

Averages

4.13

High

10.00

Mizuho

Neutral -> Outperform

upgrade

2025-07-28

Reason

Mizuho

Price Target

2025-07-28

upgrade

Neutral -> Outperform

Reason

Mizuho upgraded Alector to Outperform from Neutral with a price target of $3.50, up from $2.50. With Alector valued at roughly half its cash position of $350M, pessimism on the shares "seems overly excessive," the analyst tells investors in a research note. The firm awaits the Phase 3 data for the company's lead asset latozinemab in frontotemporal dementia, which is expected in Q4. Mizuho's key opinion feedback on latozinemab was more positive than it anticipated, and as a result it increased its probability of success to 60% from 50%. It favors the stock into the data.

H.C. Wainwright

Andrew Fein

Buy

maintain

$7 -> $10

2025-05-09

Reason

H.C. Wainwright

Andrew Fein

Price Target

$7 -> $10

2025-05-09

maintain

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on Alector to $10 from $7 and keeps a Buy rating on the shares. The INFRONT 3 topline data remains the important catalyst for this year, the analyst tells investors in a research note. The firm says AL101's "differentiated" pharmacokinetics and pharmacodynamics make it well-suited for larger indications like Alzheimer's disease. The 12-month INFRONT-2 trial results in symptomatic GRN-related frontotemporal lobar degeneration patients treated every four weeks indicated that AL001 may restore progranulin levels to normal ranges, contends H.C. Wainwright.

Morgan Stanley

Sean Laaman

Sell

Initiates

$3 → $1.5

2025-03-07

Reason

Morgan Stanley

Sean Laaman

Price Target

$3 → $1.5

2025-03-07

Initiates

Sell

Reason

Morgan Stanley analyst Sean Laaman assumed coverage of Alector with an Underweight rating and a price target of $1.50, down from $3. The firm sees no meaningful catalyst until Q4 of 2025, at which time Alector may have less than one year of cash on the balance sheet, the analyst tells investors. The firm views the latozinemab program as de-risked, but sees challenges translating results with latozinemab in FTD-GRN to AL101 in Alzheimer's disease, the analyst added.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

2025-02-27

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

2025-02-27

Reiterates

Strong Buy

Reason

Stifel

Paul Matteis

Strong Buy

Hold

Downgrades

2024-12-16

Reason

Stifel

Paul Matteis

Price Target

2024-12-16

Downgrades

Strong Buy

Hold

Reason

Cantor Fitzgerald

Pete Stavropoulos

Buy

Reiterates

n/a

2024-11-26

Reason

Cantor Fitzgerald

Pete Stavropoulos

Price Target

n/a

2024-11-26

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Alector Inc (ALEC.O) is -1.34, compared to its 5-year average forward P/E of -7.62. For a more detailed relative valuation and DCF analysis to assess Alector Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.62

Current PE

-1.34

Overvalued PE

9.31

Undervalued PE

-24.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.89

Current EV/EBITDA

0.28

Overvalued EV/EBITDA

7.65

Undervalued EV/EBITDA

-9.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

11.45

Current PS

37.76

Overvalued PS

19.94

Undervalued PS

2.96